The LIQUIDPlex™ Universal Solid Tumor panel is designed for next-generation sequencing (NGS) from circulating cell-free DNA (cfDNA), using the proprietary Anchored Multiplex PCR (AMP™) technology.

AMP™ technology (Anchored Multiplex PCR) is a proprietary targeted enrichment platform for next-generation sequencing (NGS). It is based on the use of unidirectional gene-specific primers (GSPs) and molecular adapters with unique molecular barcodes (MBCs), which are ligated to the genetic material before amplification. This strategy enables the efficient capture and amplification of DNA, RNA or cfDNA fragments, even in the presence of unknown mutations or highly fragmented sequences.

The anchored primer architecture supports a flexible design and reduces information loss during library preparation. Combined with Archer™ Analysis software, AMP™ enables systematic error correction, read deduplication and accurate quantification of original molecules, facilitating the detection of point variants, indels, gene fusions and copy number alterations with high sensitivity and specificity.

The panel is designed for use with Illumina® sequencing platforms. The workflow uses Anchored Multiplex PCR (AMP™) technology and consists of multiple steps, including two PCR rounds with gene-specific primers and adapters containing molecular barcodes (MBCs). Library preparation is completed in approximately one and a half days.

The protocol is optimized for circulating cell-free DNA (cfDNA) and supports sample inputs ranging from 5 to 300 ng, obtained from plasma or other compatible sources.